X
Xellar Biosystems
Accelerating drug discovery through human-mimetic organ-on-a-chip technology, high-fidelity 3D disease models, and AI-powered spatiotemporal profiling.
About Xellar Biosystems
Xellar Biosystems, formerly called Beijing Power Yaosu Technology, is a biotechnology startup that operates in the pharmaceutical industry, specifically in the area of drug discovery. The company leverages a unique blend of Wet Artificial Intelligence (AI), machine learning, and large-scale wet-lab experiments to address the complex challenges of modern drug discovery. Wet AI is a term used to describe the integration of AI and machine learning with biological experiments.
Read full description
The company's innovative approach aims to harness the complexity of human biology to expedite the process of drug discovery and development. Traditional methods in this field have relied on simplified models and reductionistic tools, which often fail to capture the intricate interconnections of the human body. Xellar Biosystems, however, uses a more holistic approach, recognizing that the human body is a complex, interconnected system.
Xellar Biosystems' business model is likely based on partnerships with pharmaceutical companies and research institutions. By offering its advanced drug discovery platform, the company can help these entities accelerate their drug development processes, potentially saving them significant time and resources. This, in turn, could lead to faster approval and commercialization of new drugs, providing a valuable service to the pharmaceutical industry.
In terms of revenue generation, Xellar Biosystems likely charges for access to its platform and services, possibly on a subscription or per-use basis. The company could also generate income through strategic partnerships, licensing agreements, or by offering additional services such as data analysis or consulting.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Boston, United States
- Employees
- 27
- Open positions
- 1
- Dealroom signal
- 88.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development
- Technology
- Artificial Intelligence, Hardware, Deep Tech, Machine Learning, Deep Learning, Nanotech, Computer Vision
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2026 | $29M | $118M | Oriental Fortune Capital · Yael Capital Management · Cedarlake Capital · GF Securities | ↗ |
| SERIES AOther financing | Apr 2026 | $29M | $116M | Yayi Capital · China Life Private Equity Investment · Legend Capital · XtalPi | ↗ |
Growth signals
Latest recorded traffic for Xellar Biosystems is 790 monthly website visits, down 76.1% over the last three months. Xellar Biosystems's team grew 22.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Legend Capital
TriApex Laboratories
Tiantu Capital
Yael Capital Management- ZIZhengxuan Investment
- CIChina Life Private Equity Investment
- YCYayi Capital
XtalPi
Oriental Fortune Capital
Cedarlake Capital
GF Securities- QCQingsong Capital
Other known investors1 additional known investor
Northeastern University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xellar Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xellar Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







